NCT02887040: An ongoing trial by Burzynski Research Institute
This trial is ongoing. It must report results 1 year, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT02887040 |
|---|---|
| Title | A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 1, 2025 |
| Completion date | June 30, 2026 |
| Required reporting date | June 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |